Cargando…
EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy
PD-L1 expression is a feature of Epstein-Barr virus (EBV) associated malignancies such as nasopharyngeal carcinoma (NPC). Here, we found that EBV-induced latent membrane protein 1 (LMP1) and IFN-γ pathways cooperate to regulate programmed cell death protein 1 ligand (PD-L1). Expression of PD-L1 was...
Autores principales: | Fang, Wenfeng, Zhang, Jianwei, Hong, Shaodong, Zhan, Jianhua, Chen, Nan, Qin, Tao, Tang, Yanna, Zhang, Yaxiong, Kang, Shiyang, Zhou, Ting, Wu, Xuan, Liang, Wenhua, Hu, Zhihuang, Ma, Yuxiang, Zhao, Yuanyuan, Tian, Ying, Yang, Yunpeng, Xue, Cong, Yan, Yue, Hou, Xue, Huang, Peiyu, Huang, Yan, Zhao, Hongyun, Zhang, Li |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4322961/ https://www.ncbi.nlm.nih.gov/pubmed/25361008 |
Ejemplares similares
-
PD-L1 is remarkably over-expressed in EBV-associated pulmonary lymphoepithelioma-like carcinoma and related to poor disease-free survival
por: Fang, Wenfeng, et al.
Publicado: (2015) -
A Large-scale Cross-sectional Study of ALK Rearrangements and EGFR Mutations in Non-small-cell Lung Cancer in Chinese Han Population
por: Hong, Shaodong, et al.
Publicado: (2014) -
Multi-Targeted Antiangiogenic Tyrosine Kinase Inhibitors in Advanced Non-Small Cell Lung Cancer: Meta-Analyses of 20 Randomized Controlled Trials and Subgroup Analyses
por: Liang, Wenhua, et al.
Publicado: (2014) -
EGFR mutation genotypes affect efficacy and resistance mechanisms of osimertinib in T790M-positive NSCLC patients
por: Zheng, Qiufan, et al.
Publicado: (2020) -
EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients
por: Zheng, Qiufan, et al.
Publicado: (2020)